Phase Ib/II study of BCL-2 inhibitor lisaftoclax (APG-2575) safety and tolerability when administered alone or combined with a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor in patients with estrogen receptor-positive (ER plus ) breast cancer or advanced solid tumors-MedSci.cn

Phase Ib/II study of BCL-2 inhibitor lisaftoclax (APG-2575) safety and tolerability when administered alone or combined with a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor in patients with estrogen receptor-positive (ER plus ) breast cancer or advanced solid tumors

Kalinsky, K; Tolcher, AW; Wang, SS; Meric-Bernstam, F; Winkler, R; Li, MY; Sun, XM; Pan, WT; Paudyal, B; Liang, ZY; Lu, M; Yang, DJ; Zhai, YF

JOURNAL OF CLINICAL ONCOLOGY, 2022; 40 (16):

科室
- - 订阅+
  - 更多科室
工具
服务